Ann: 31 December Financial Report , page-12

FACT:
Revenues are up 1168%
FACT:
STI has just received $829,000 in funding.
FACT:
Canadian Plant, Telemedcare, HDA and other IP's in progress.
FACT:
Notwithstanding dividends but STI has outperformed TLS in share price for the last 2 years since PB AND Board took over STI that was a basket case.

FACT:
Revenues mean squat without consideration to margins, cash flow positive necessary for survival.
FACT:
STI continues to go to the market for handouts. The only thing positive about receiving yet another one is that it means the company has a bit more time, but the trend overall, continual cap raisings, is not a positive one. Have we any guarantees on what the funds will be used for - 4 months worth of administration expenses, or getting the pharma plant into gear? What are the odds of being cash flow positive before the next cap raising? Will PB decide to buy a penthouse on the side, or buy rights to a new product to expand the company portfolio? These are the uncertainties faced by the market.
FACT:
All IP's are ostensibly 'in progress', there is a lack of certainty as to when projects will be complete, not helped by continual blowout of deadlines.
FACT:
Company two years ago was a basketcase as you say. This record low is hardly a fair baseline for comparing stock price, buyers at the time would have been taking a gamble (that paid off) that the company would not go into administration. The price trend since the 'new STI' emerged hasn't been so rosy.